| Value | ₹0.49 Cr |
|---|
BSE filing, NSE: LALPATHLAB. Summary written from the filing by ALFA Finder's alert engine.
Dr. Lal Pathlabs Ltd: key numbers
- Share price
- ₹2,045.00
- Market cap
- ₹34,325 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 58.8×Sector 53.8×
- Promoter holding
- 52.93%-0.26% QoQ
- FII holding
- 18.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lal Pathlabs Ltd
All →Dr. Lal Pathlabs Management Change
Dr. Lal Path Labs appointed Ms. Vasuta Agarwal as an additional Non-Executive Independent Director for three years from 4 November 2026. Her appointment is subject to member approval by postal ballot.
- Execution
- 36 months from 04-11-2026
Dr. Lal Pathlabs Capital Structure Change
Dr. Lal PathLabs will invest up to Rs 49.5 Crore in its wholly owned Dubai subsidiary, in tranches. Funds cover operations and further investment in Ghana's SHL.
- Value
- ₹49.50 Cr
- Execution
- Indicative completion by 31 March 2027, in tranches
Dr. Lal Pathlabs Dividend
Dr. Lal Path Labs approved a Rs 5 per share second interim dividend. Record date is November 11, 2026; payment by December 3, 2026.
Dr. Lal Pathlabs Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 874 Cr (+19.6%), EBITDA Rs 280 Cr (32.1% margin), PAT Rs 194 Cr (+27.5%). Strategy: AI diagnostics, rural GraminFit, M&A.
Dr. Lal Pathlabs Q2 FY27 Results: Net Profit ₹193.9 Cr, Up 27.4% YoY
Dr. Lal Pathlabs Ltd reported revenue from operations of ₹873.9 Cr (+19.6% YoY) and net profit of ₹193.9 Cr (+27.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹193.9 Cr · +27.4% YoY
Dr. Lal Pathlabs Board Meeting Date
Dr. Lal PathLabs updated its 4 November 2026 board meeting notice to add a possible second interim dividend. The meeting will also approve unaudited quarterly results.
Other capital structure change announcements
All →Jyothy Labs Capital Structure Change
Jyothy Labs' board approved a Rs 147 Crore share buyback via tender offer at Rs 215 per share. The record date is November 11, 2026.
- Value
- ₹147.0 Cr
Evonile Pharma Capital Structure Change
Evonile Pharma's Rights Issue Committee fixed November 11, 2026 as record date for a partly paid rights issue of 1,02,87,832 shares at Rs.860 each. Issue size is Rs.8,847.54 Million, with issue opening November 19, 2026.
- Value
- ₹884.8 Cr
- Execution
- Issue opening 19 Nov 2026 to closing 3 Dec 2026; listing on or about 9 Dec 2026
Share India Securities Capital Structure Change
Share India Securities allotted 44,02,000 equity shares under its Silverleaf Capital amalgamation scheme. It also granted 3,80,500 employee stock options under ESOS-II.
Arvaya Healthcare Capital Structure Change
Arvaya Healthcare's board approved the draft letter of offer for a rights issue of partly paid-up equity shares up to ₹210 Crore, plus a postal ballot. The board outcome's main decision is the rights issue, so it is classified as a capital raise step.
- Value
- ₹210.0 Cr
Mittal Life Style Capital Structure Change
Mittal Life Style set 15 December 2026 as the record date for a 10:1 consolidation of its equity shares. No cash is paid.
Zodiac JRD MKJ Capital Structure Change
Zodiac-JRD-MKJ approved final terms of its Rs 40 crore rights issue at Rs 25 per share. Issue runs 19 November to 3 December 2026.
- Value
- ₹40.00 Cr